Welcome to our dedicated page for Immunovant SEC filings (Ticker: IMVT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking Immunovant’s journey from discovery to late-stage trials means wading through pages of scientific jargon and cash-flow tables. The latest annual report details anti-FcRn antibody engineering, while every 8-K discloses clinical milestones that can move the share price overnight. If you have ever typed “Immunovant SEC filings explained simply” or “How do I read Immunovant’s quarterly earnings report 10-Q filing?” you know the challenge.
Stock Titan’s AI-powered analysis turns each document into clear, skimmable insights. Our platform highlights where the 10-K reveals batoclimab safety data, flags liquidity risks inside the 10-Q, and alerts you to “Immunovant insider trading Form 4 transactions” the moment they post to EDGAR. Need “Immunovant 8-K material events explained”? We annotate trial updates line-by-line, while real-time push notices track “Immunovant Form 4 insider transactions real-time” and upcoming votes on executive pay.
- AI summaries of every Immunovant annual report 10-K simplified
- Side-by-side comparisons across sequential 10-Q filings
- Instant alerts for insider buys, sells, and option grants
Whether you monitor R&D spend, compare pipeline timelines, or follow “Immunovant proxy statement executive compensation,” all filings are one click away. Use our technology for “Immunovant earnings report filing analysis,” dive deep into cash runway tables, or export Form 4 data on “Immunovant executive stock transactions Form 4.” Professional investors rely on Stock Titan to surface hidden details fast—so you can act on information, not search for it.
Immunovant is a clinical-stage immunology company advancing two anti-FcRn antibodies, IMVT-1402 and batoclimab. For the quarter ended June 30, 2025 the company reported a net loss of $120.6 million versus $87.2 million a year earlier, driven by higher research and development ($101.2 million versus $75.5 million) and increased general and administrative expense ($26.0 million versus $18.8 million). Cash and cash equivalents totaled $598.9 million at quarter end, down from $714.0 million three months earlier, and cash used in operations was $117.4 million.
The company has initiated multiple potentially registrational IMVT-1402 trials across Graves disease, myasthenia gravis, CIDP, difficult-to-treat rheumatoid arthritis, Sj f6grens disease and a CLE proof-of-concept study, and expects a Graves disease readout in 2027. Batoclimab Phase 3 top-line results in thyroid eye disease are expected in the second half of 2025. Contractual commitments include an estimated $43.1 million remaining minimum purchase obligation to Samsung and potential milestone payments under the HanAll license up to $420.0 million (after $32.5 million previously paid).
FAQ
What is the current stock price of Immunovant (IMVT)?
What is the market cap of Immunovant (IMVT)?
